The FDA and United Nations Are Exploring the Benefits of CBD in Public Comment Request
On a request from the United Nations, which is exploring how to categorize CBD and various other drugs according to the 1971 Convention on Psychotropic Substances, the Food and Drug Administration has issued a public request for comment on the positives and Negatives of CBD. In the request the FDA acknowledged CBD's medical potential:
Cannabidiol (CBD) is one of the active cannabinoids identified in cannabis. CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.
CBD is legal nationally, but it is not approved for medical use by the FDA. Although the FDA has issued the public comment request on behalf of the UN, it could be a sign that CBD is inching closer to FDA approval, which would be a major victory for its accessibility in the medical marketplace.
Anybody is encouraged to comment before the deadline in mid-September. Besides CBD, the public comment request includes other substances such as Ketamine, a 'party drug' that has shown a lot of potential as an antidepressant.